- Finest ESG ranking tier of negligible-risk with a leading 1% worldwide ranking rating
- Market and Regional ESG Top-Rated Business for 5 successive years
- Leader in Green CRDMO to drive development for a much healthier future
SHANGHAI, July 16, 2025/ PRNewswire/– WuXi Biologics (2269. HK), a leading worldwide Agreement Research study, Advancement, and Production Company (CRDMO), today revealed it has actually raised its Morningstar Sustainalytics ESG ranking score to the greatest negligible-risk tier, showing its management in the worldwide pharmaceutical market.
Sustainalytics is a leading ESG information, research study, and scores company that supports worldwide financiers with their advancement and execution of accountable financial investment techniques. Its 2025 ESG Threat Scores– covering more than 15,000 business throughout various markets worldwide– assesses over 20 product ESG problems through over 200 indications and classifies ranking outcomes throughout 5 threat levels, from the very best minimal to the worst serious.
Under the two-dimensional evaluation structure, WuXi Biologics accomplished the most affordable level of threat direct exposure and was provided the greatest threat management rating, positioning it in the negligible-risk tier with a leading 1% worldwide ranking. In addition, for the 5th successive year, the business has actually been acknowledged by Morningstar Sustainalytics as a Market and Regional ESG Top-Rated Business.
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, ” We are really delighted to have actually accomplished the negligible-risk ranking from Morningstar Sustainalytics. It is a reflection of and acknowledgment for WuXi Biologics’ constant dedication to boosting sustainability abilities. As a worldwide leader in Green CRDMO, we are focused not just on providing our own ESG quality however likewise on making it possible for partners worldwide to satisfy their ESG dedications, working together with all stakeholders to promote accountable practices throughout the whole worth chain.”
As an individual of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Effort (PSCI), the business proactively adds to promoting sustainability and has actually made prevalent acknowledgments for its efforts. It has actually been approved a MSCI AAA ranking; granted an EcoVadis Platinum Medal; noted in the Dow Jones Sustainability Indices (DJSI); called to the CDP Water Security “A list” and provided an A- CDP Environment Modification leadership-level rating because 2023; picked as a Constituent of the FTSE4Good Index Series; noted in the Hang Seng ESG 50 Index; and ranked as Prime by ISS ESG Corporate Ranking.
About Morningstar Sustainalytics
Morningstar Sustainalytics is a leading ESG information, research study, and scores company that supports financiers around the globe with the advancement and execution of accountable financial investment techniques. For more than thirty years, the company has actually been at the leading edge of establishing top quality, ingenious options to fulfill the developing requirements of worldwide financiers. Today, Morningstar Sustainalytics deals with numerous the world’s prominent property supervisors and pension funds who integrate ESG info and evaluations into their financial investment procedures. The company likewise deals with numerous business and their monetary intermediaries to assist them think about product sustainability consider policies, practices, and capital jobs. Morningstar Sustainalytics has experts around the globe with different multidisciplinary competence throughout more than 40 market groups. To learn more, see www.sustainalytics.com.
About WuXi Biologics
WuXi Biologics (stock code: 2269. HK) is a leading worldwide Agreement Research study, Advancement and Production Company (CRDMO) offering end-to-end options that allow partners to find, establish and make biologics– from idea to commercialization– for the advantage of clients worldwide.
With over 12,000 proficient workers in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its innovations and competence to supply clients with effective and economical biologics discovery, advancement and production options. Since December 31, 2024, WuXi Biologics is supporting 817 incorporated customer jobs, consisting of 21 in business production (omitting COVID CMO jobs).
WuXi Biologics concerns sustainability as the foundation of long-lasting organization development. The business constantly drives green innovation developments to provide innovative end-to-end Green CRDMO options for its worldwide partners while regularly accomplishing quality in Environment, Social and Governance (ESG). Dedicated to producing shared worth, it teams up with all stakeholders to cultivate favorable social and ecological effects and promote accountable practices that empower the whole worth chain.
To learn more about WuXi Biologics, please see: www.wuxibiologics.com.
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
SOURCE WuXi Biologics